Romans Zukovs

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Epithelial Mesenchymal Transition

Multiple Myeloma

Induced Apoptosis

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Lucienne Bogun, Annemarie Koch, Bo Scherer, Roland Fenk, Uwe Maus, Felix Bormann, Karl Köhrer, Patrick Petzsch, Thorsten Wachtmeister, Romans Zukovs, Sascha Dietrich, Rainer Haas, Thomas Schroeder, Paul S Jäger, Stefanie Geyh
Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. Blood advances 8 (10) (2024)
Lucienne Bogun, Annemarie Koch, Bo Scherer, Roland Fenk, Uwe Maus, Felix Bormann, Karl Köhrer, Patrick Petzsch, Thorsten Wachtmeister, Romans Zukovs, Sascha Dietrich, Rainer Haas, Thomas Schroeder, Paul S Jäger, Stefanie Geyh
Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. Blood advances 8 (10) (2024)
Lucienne Bogun, Annemarie Koch, Bo Scherer, Roland Fenk, Uwe Maus, Felix Bormann, Karl Köhrer, Patrick Petzsch, Thorsten Wachtmeister, Romans Zukovs, Sascha Dietrich, Rainer Haas, Thomas Schroeder, Paul S Jäger, Stefanie Geyh
Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. Blood advances 8 (10) (2024)
Lucienne Bogun, Annemarie Koch, Bo Scherer, Roland Fenk, Uwe Maus, Felix Bormann, Karl Köhrer, Patrick Petzsch, Thorsten Wachtmeister, Romans Zukovs, Sascha Dietrich, Rainer Haas, Thomas Schroeder, Paul Sebastian Jäger, Stefanie Geyh
Stromal alterations in patients with MGUS, smoldering myeloma and multiple myeloma. Blood advances (2024)
Amelie Boquoi, Veronika Rings, Annemarie Mohring, Ingrida Savickaite, Romans Zukovs, Judith Strapatsas, Kathrin Nachtkamp, Guido Kobbe, Ulrich Germing, Roland Fenk
Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations. Cancers 14 (9) (2022)